Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > current valuation

<< Previous

Bullboard Posts

Next >>

Comment by bringon10baggeron Jan 26, 2021 6:00pm

229 Views

Post# 32391865

RE:current valuation

I guess that article didn't do much to attract many new investors...........lol...

cashcrab wrote: Simply wall st. has an article on atbpf and puts current value at $59 canadian and says it is 93% undervalued. not sure about the math on this last statement but I found it reassuring! another positive point they made was that they have no debt. They are financed as we know by shareholders. While many on here cry about dillution, it is better than debt.The shares can increase in value and all developement costs are gone. Debt doesnt go away on its own,so I approve of their method.

<< Previous

Bullboard Posts

Next >>

BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide